regulatory_compliance

Minneapolis – September 04, 2026 -- The American Academy of Neurology (AAN) and American Headache Society (AHS) have issued a joint update to their 2012 clinical practice guideline on migraine prevention medications for adults, published simultaneously in Neurology and Headache journals on August 31, 2026.

Guideline sets clear treatment threshold for clinicians

The update recommends preventive treatment for patients experiencing four or more migraine days per month, four or more moderate-to-severe headache days per month, or migraine that impairs their ability to work or complete daily tasks. It distinguishes between chronic migraine, defined as 15 or more headache days a month with at least eight showing migraine features, and episodic migraine, which occurs on fewer days per month.

STOCKHOLM – September 04, 2026 -- Canada's Drug Agency (CDA-AMC) has issued a final recommendation supporting public reimbursement of Leqembi (lecanemab) for patients with mild cognitive impairment or mild dementia due to early Alzheimer's disease, BioArctic AB's partner Eisai announced.

Final recommendation follows agency reconsideration process

The decision comes after CDA-AMC reconsidered its position on the drug, marking a step toward broader patient access in Canada. Negotiations will now proceed through the pan-Canadian Pharmaceutical Alliance, followed by individual reimbursement decisions from public drug plans across Canada's provinces and territories.

Fort Lauderdale, Florida – September 04, 2026 -- IGEL has added Teguar to its IGEL Ready ecosystem, certifying the manufacturer's rugged and specialized hardware for use with IGEL OS in healthcare, manufacturing and warehouse settings.

Teguar brings purpose-built systems for environments unsuited to commercial-grade devices

Teguar's portfolio includes rugged, waterproof industrial computers alongside all-in-one systems and tablets designed for clinical use. The hardware targets operational conditions where standard commercial endpoints fail to meet durability or workflow requirements.

DELRAY BEACH, FLA. – September 04, 2026 -- The global PTFE membranes market is projected to reach $2.84 billion by 2031, up from $2.14 billion in 2026, expanding at a compound annual growth rate of 5.8%, according to MarketsandMarkets.

Asia Pacific commands 42.2% market share as region emerges fastest-growing

Asia Pacific accounted for 42.2% of the PTFE membranes market in 2026, driven by industrial expansion, pharmaceutical and biotechnology manufacturing, and semiconductor production across China, India, Japan, South Korea, and Southeast Asia. The region is also expected to post the fastest growth through 2031, as countries increase investment in advanced manufacturing, healthcare infrastructure, and water treatment capacity.

Guangzhou – September 03, 2026 -- Guangzhou Shangpin Packaging Products Co., Ltd. (Sprintpackage) has doubled to tripled its annual paper tube production output after relocating operations to a new 20,000-square-meter facility in the No. 1 Hard Technology Industrial Park, Baiyun District, Guangzhou, completed in June 2026.

Six automated lines push daily capacity to 300,000 units

The new plant runs six fully automated production lines covering tube winding, slitting, paper mounting, curling, and final assembly in-house. With automation exceeding 80%, Sprintpackage now produces between 200,000 and 300,000 tube units daily, supplying buyers primarily across Europe and the Middle East.

INDIANAPOLIS – September 03, 2026 -- Eli Lilly and Company reported that combining Taltz (ixekizumab) with Zepbound (tirzepatide) sustained or deepened efficacy at 52 weeks in patients with psoriatic disease and obesity, building on statistically superior results already seen at Week 36 versus Taltz alone.

Combination therapy nearly triples complete skin clearance response rates

In the TOGETHER-PsO trial, 30.6% of patients on the combination achieved PASI 100 plus at least 10% weight loss at Week 52, compared with 4.4% on Taltz monotherapy. Complete skin clearance alone (PASI 100) was maintained by 40.5% of combination patients versus 29.1% on monotherapy.

Dublin – September 03, 2026 -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) reported that Ziihera (zanidatamab-hrii) combined with chemotherapy produced a statistically significant and clinically meaningful overall survival (OS) benefit versus trastuzumab plus chemotherapy in a second interim analysis of the Phase 3 HERIZON-GEA-01 trial in first-line HER2-positive gastroesophageal adenocarcinoma (GEA).

OS hazard ratio for Ziihera plus chemotherapy improved versus the first interim analysis

The company said the survival advantage strengthened compared with earlier data, reinforcing Ziihera's position following its FDA approval on August 25, 2026. No new safety signals emerged relative to previously reported HERIZON-GEA-01 data or the known profiles of the individual agents.

WASHINGTON – September 03, 2026 -- The National Petroleum Council (NPC) has issued nine recommendations urging Congress and federal agencies to launch a coordinated national program to assess America's subsurface energy and mineral resources, warning that over 80% of the country's energy needs depend on assets that remain largely unmapped for decades.

The report, titled "American Resources for a Secure Future: A National Cooperative Subsurface Assessment Program," was commissioned by U.S. Secretary of Energy Chris Wright and developed by roughly 80 experts spanning state government, Tribal organizations, industry, and academia. It was approved by a full vote of NPC membership.

Hong Kong – September 03, 2026 -- Ascletis Pharma Inc. has dosed the first participant in a global Phase III program for ASC30, an oral small molecule GLP-1 receptor agonist for chronic weight management, the Hong Kong Stock Exchange-listed biotech confirmed.

Trial enrolls 4,600 participants across three continents

The program comprises two pivotal trials, AURORA-1 and AURORA-2, spanning clinical sites in the U.S., Europe, and Canada. AURORA-1 targets participants with obesity or overweight without type 2 diabetes, while AURORA-2 enrolls those with type 2 diabetes; both trials test 20 mg, 40 mg, and 60 mg maintenance doses against placebo over 72 weeks, with the primary endpoint measuring percentage change in body weight from baseline to Week 72.

ALTAMIRA, MEXICO -- August 31, 2026 -- Christian Hess Ratz, Jurgen Hess Ratz and Steel Connect, B.V. have launched an American Arbitration Association (AAA) proceeding against LOGISTEC Marine Services ULC and LOGISTEC Stevedoring Canada Inc., seeking to force completion of a stalled acquisition of IPA Steel Terminal in Altamira, Mexico.

LOGISTEC announced the $100%-stake acquisition of IPA Terminal in February 2026

On February 17, 2026, Canadian marine logistics operator LOGISTEC announced a definitive agreement to acquire 100% of IPA Terminal, a breakbulk and steel-handling facility at the Port of Altamira. Mexican and Canadian officials publicly praised the deal as a boost to bilateral trade ties. The transaction followed a full due-diligence review in which sellers disclosed complete operational, financial and cargo-origin records to LOGISTEC.